2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Precancerous Conditions
4
Colorectal Neoplasms
4
Breast Neoplasms
4
Adenomatous Polyposis Coli
4
Neoplasms
3
Colonic Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Tobacco Use Disorder
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Intraductal Neoplasms
1
Pain
1
Melanoma
1
Leukoplakia, Oral
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Hypertension
1
Desmoid Tumors
1
Coproporphyria
1
Colonic Polyps
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Carcinoma In Situ
1
Aberrant Crypt Foci
1
Interventions
Cytarabine
561
Azacitidine
385
venetoclax
311
Cyclophosphamide
289
fludarabine
246
fludarabine phosphate
229
Decitabine
187
Busulfan
176
Daunorubicin
155
Idarubicin
151
Peripheral Blood Stem Cell Transplantation
138
Mycophenolic Acid
134
Filgrastim
134
Whole-Body Irradiation
133
Tacrolimus
125
Granulocyte Colony-Stimulating Factor
124
Etoposide
117
Mitoxantrone
103
Methotrexate
103
Melphalan
103
Cyclosporine
101
Antilymphocyte Serum
85
Gemtuzumab
84
Clofarabine
84
Specimen Handling
73
Injections
69
Stem Cell Transplantation
64
Biopsy
57
CPX-351
56
Thiotepa
54
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Acute
×
Sulindac
×
Clear all
NCT01843179
2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2
Withdrawn